Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy

SUMMARY: BACKGROUND AND OBJECTIVES: In ADOPT (A Diabetes Outcomes Prevention Trial), initial monotherapy with rosiglitazone provided more durable glycemic control than metformin or glyburide in patients with recently diagnosed type 2 diabetes. Herein, we examine differences in albumin excretion, ren...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lachin, John M., Viberti, Giancarlo, Zinman, Bernard, Haffner, Steven M., Aftring, R. Paul, Paul, Gitanjali, Kravitz, Barbara G., Herman, William H., Holman, Rury R., Kahn, Steven E.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2011
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3087768/
https://ncbi.nlm.nih.gov/pubmed/21454723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.09291010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars